Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.02.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Yi-Han Tseng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan. Hauptthemen laut MEDLINE: Prodrugs, Irinotecan, Glucuronidase, Camptothecin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Academia Sinica, National Laboratory Animal Center, Institute of Biomedical Sciences, Academia Sinica.
Abstract (Originalsprache)
Engineering human enzymes for therapeutic applications is attractive but introducing new amino acids may adversely affect enzyme stability and immunogenicity. Here we used a mammalian membrane-tethered screening system (ECSTASY) to evolve human lysosomal beta-glucuronidase (hBG) to hydrolyze a glucuronide metabolite (SN-38G) of the anticancer drug irinotecan (CPT-11). Three human beta-glucuronidase variants (hBG3, hBG10 and hBG19) with 3, 10 and 19 amino acid substitutions were identified that display up to 40-fold enhanced enzymatic activity, higher stability than E. coli beta-glucuronidase in human serum, and similar pharmacokinetics in mice as wild-type hBG. The hBG variants were two to three orders of magnitude less immunogenic than E. coli beta-glucuronidase in hBG transgenic mice. Intravenous administration of an immunoenzyme (hcc49-hBG10) targeting a sialyl-Tn tumor-associated antigen to mice bearing human colon xenografts significantly enhanced the anticancer activity of CPT-11 as measured by tumor suppression and mouse survival. Our results suggest that genetically-modified human enzymes represent a good alternative to microbially-derived enzymes for therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.
- Vinča Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade 11001, Serbia.
- Department of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan 71710, Taiwan.
- Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. Electronic address: sroff@ibms.sinica.…
Förderung
- Academia Sinica
- National Laboratory Animal Center
- Institute of Biomedical Sciences, Academia Sinica
- National Science and Technology Council
Zitieren
APA
Tseng, Y. H., Lin, H. P., Lin, S. Y., Chen, B. M., Vo, T. N. N., Yang, S. H., Lin, Y. C., Prijovic, Z., Czosseck, A., Leu, Y. L., & Roffler, S. R. (2024). Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.02.026
Vancouver
Tseng YH, Lin HP, Lin SY, Chen BM, Vo TNN, Yang SH, et al. Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.02.026
BibTeX
@article{Tseng2024,
author = {Tseng, Yi-Han and Lin, Hsuan-Pei and Lin, Sung-Yao and Chen, Bing-Mae and Vo, Thanh Nguyet Nguyen and Yang, Shih-Hung and Lin, Yi-Chen and Prijovic, Zeljko and Czosseck, Andreas and Leu, Yu-Lin and Roffler, Steve R},
title = {Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.02.026}
}
EUVIMED